Abstract | BACKGROUND: METHODS: Nineteen patients, 34-65 years of age, were treated with a new radioimmunoconjugate, 90Y-CITC-DTPA-HMFG1, instilled in the peritoneal cavity after second-look laparoscopy. Activity was increased in a stepwise fashion. RESULTS: Following the intraperitoneal administration of 90Y-CITC-DTPA-HMFG1, levels of the radioimmunoconjugate in the blood increased, reaching a peak of about 30% of injected activity at around 54 hours posttreatment. Approximately 18% of the radiolabel was excreted in the urine within 96 hours. Bone-marrow toxicity was the dose-limiting factor. Grade III platelet and granulocyte toxicity was observed at 19.3 mCi/m2. A type III immunologic response was observed in a number of patients. CONCLUSIONS: A dose of 18.5 mCi/m2 for subsequent treatments is recommended, based on a linear correlation of activity dose-to-body surface area. The clinical profile of a mild to moderate hypersensitivity syndrome is presented and hypotheses regarding its etiology are suggested.
|
Authors | A Maraveyas, D Snook, V Hird, C Kosmas, C F Meares, H E Lambert, A A Epenetos |
Journal | Cancer
(Cancer)
Vol. 73
Issue 3 Suppl
Pg. 1067-75
(Feb 01 1994)
ISSN: 0008-543X [Print] United States |
PMID | 8306249
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Mucins
- Yttrium Radioisotopes
|
Topics |
- Adult
- Aged
- Animals
- Antibodies, Monoclonal
(metabolism, therapeutic use)
- Brachytherapy
- Female
- Humans
- Mice
(immunology)
- Middle Aged
- Mucins
(immunology)
- Ovarian Neoplasms
(radiotherapy)
- Radioimmunotherapy
(adverse effects)
- Yttrium Radioisotopes
(administration & dosage, pharmacokinetics, therapeutic use, toxicity)
|